Calithera Biosciences

CALA · OTC

$0.00+$0.0001 (−100.00%)TodayMarket closed ·
Prev close -$0.0001

About CALA

Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The firm is winding up its operations. The firm is seeking to sell all of its clinical assets and programs. The firm has not generated any revenue.

Employees
8
Headquarters
South San Francisco, California
Listed
Oct 2, 2014
Sector
Health Care
Industry
Biotechnology

CALA key statistics

Market cap
5
Price-earnings ratio
0.00
Dividend yield
—
Average volume
183
Volume
7
Open price
$0.0005
High today
$0.0005
Low today
$0.00
52 Week high
$0.001
52 Week low
$0.00

Calithera Biosciences (CALA) at a glance

Calithera Biosciences (CALA) last traded at $0.00, with a market cap of 5 and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.00 and $0.0005. The current price is — above the day's low and 100.0% below its high.

Volume so far is 7 shares, below the average of 183 shares a day.

Over the past year Calithera Biosciences has ranged from $0.00 to $0.001, and now sits 0% of the way up that range.

Calithera Biosciences met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q3 FY22 it reported -$2.01 per share against an estimate of -$1.97.

CALA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 15.6% on average.

  1. Q4 FY20: reported -$6.40 per share against an estimate of -$6.61
  2. Q1 FY21: reported -$5.60 per share against an estimate of -$5.63
  3. Q2 FY21: reported -$3.80 per share against an estimate of -$4.90
  4. Q3 FY21: reported -$3.00 per share against an estimate of -$4.65
  5. Q4 FY21: reported -$4.80 per share against an estimate of -$4.90
  6. Q1 FY22: reported -$3.60 per share against an estimate of -$3.77
  7. Q2 FY22: reported -$1.59 per share against an estimate of -$2.71
  8. Q3 FY22: reported -$2.01 per share against an estimate of -$1.97

Similar companies

Companies in the same industry as Calithera Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.